Based in Sweden, Atrogi is a startup.
Atrogi is a clinical-stage biotechnology company developing first-in-class small-molecule, once-daily oral therapies targeting the beta-2 adrenergic receptor for metabolic disorders. Its lead asset, ATR-258, has completed a Phase I safety study and the company is positioned as Phase II–ready for indications including type 2 diabetes, obesity and muscle-wasting.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.